William T Johnson

11PUBLICATIONS
78CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

|Mar 04, 2026
How I treat HLH-like toxicities after immune effector cell therapy.

William T Johnson, Kevin O McNerney, Matthew J Frank

|Dec 10, 2025
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Joseph M Rocco, Joseph H Oved, Rikita J Patel

|Sep 09, 2025
"Optimizing" HLH diagnoses in patients with lymphoma.

Joseph M Rocco, William T Johnson

|Dec 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Pallawi Torka, Tatyana Feldman, Kerry J Savage

|Apr 09, 2024
Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and/or NK-cell lymphoma.

Ying Liu, Rohan Sardana, David Nemirovsky

Pageof 2

Frequent Collaborators

7 joint publications

Santosha Vardhana

7 joint publications

Ahmet Dogan

6 joint publications

Andrew D Zelenetz

6 joint publications

Gilles Salles